剂泰科技完成4亿元D轮融资 发布Open CGT递送平台

Group 1 - JiTai Technology has completed a Series D financing round, raising a total of 400 million RMB, led by Beijing Medical Health Industry Investment Fund and Daxing District Industrial Investment Fund [1] - The funds will accelerate JiTai Technology's strategic initiatives, including platform automation upgrades, self-developed product pipeline advancement, deepening international strategic cooperation, and attracting high-end talent [1] - JiTai Technology launched the Open CGT delivery platform, focusing on addressing industry pain points in precise drug delivery, aiming to lower development thresholds and costs for breakthrough cell and gene therapy (CGT) research and clinical transformation [1] Group 2 - The Open CGT delivery platform is designed to integrate research capabilities from top universities, resources from major hospitals, and the entire R&D chain of innovative CGT pharmaceutical companies in Beijing [1] - The platform has initiated its first project, enabling Rui Zheng Gene to develop an mRNA-LNP-based liver-targeted CRISPR gene editing therapy [1] - The Beijing Medical Health Industry Investment Fund is one of eight industry funds approved by the Beijing government, focusing on innovative drugs, medical devices, and emerging industries like cell and gene therapy and digital healthcare [1] Group 3 - The chairman of Shunxi Management Company emphasized that the medical and health sector is crucial for Beijing's innovative development and the cultivation of new productive forces [2] - Beijing has established a 20 billion RMB medical health industry investment fund, focusing on innovative drugs, medical devices, cell and gene therapy, and digital healthcare [2] - JiTai Technology's Open CGT delivery platform fills a critical gap in the transformation of high-end formulations and delivery systems, aiding Beijing in becoming an international innovation hub for CGT [2] Group 4 - The chairman of Daxing District Investment Group stated that Daxing District is committed to making the biopharmaceutical industry a core track for high-quality development [2] - The CGT sector is identified as the main track for third-generation drug innovation, following small molecule drugs and antibody drugs [2] - A three-year action plan for accelerating innovation in the cell and gene therapy industry in Beijing aims to cultivate over 20 leading-edge technology companies in the CGT field by 2027 [2]